Issue Archive
Table of Contents
BLOOD ADVANCES TALK
REVIEW ARTICLE
CLINICAL TRIALS AND OBSERVATIONS
Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors
Clinical Trials & Observations
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma
Clinical Trials & Observations
HEMATOPOIESIS AND STEM CELLS
LYMPHOID NEOPLASIA
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
RED CELLS, IRON, AND ERYTHROPOIESIS
TRANSPLANTATION
Haploidentical transplant in patients with myelodysplastic syndrome
Clinical Trials & Observations
Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease
Clinical Trials & Observations
-
Cover Image
Cover Image
![issue cover]()
COVER FIGURE
HLA loss is sufficient for clonal expansion but does not prevent clonal evolution. The diagram shows three types of clonal architecture found in patients with somatic HLA loss. (Top) Four patients had oligoclonal hematopoiesis with multiple independent events of HLA loss, without other nonsynonymous or regulatory region somatic mutations. (Middle) One patient had HLA loss and somatic mutations occurring in independent clones, where the clone bearing myelodysplastic syndrome–associated mutations expanded to replace the clone with HLA loss. (Bottom) Two patients were found to have oligoclonal hematopoiesis with clones missing HLA alleles occurring in the same cells as somatic mutations, which either were subclonal or co-occurred with HLA loss in all cells analyzed. See the article by Babushok et al. - PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkEditorial Board
